Each year 640, 000 people are diagnosed with head and neck tumor and some 350,000 die from the condition which includes cancers of the mouth, salivary glands, paranasal sinuses and nasal cavity, pharynx and larynx. The trial discovered that when Taxotere was given in conjunction with 5-fluorouracil and cisplatin, the chance of death in cancers patients was reduced by thirty % compared to patients receiving just cisplatin and 5-fluorouracil. The survival in the Taxotere group was 70.6 months in comparison to 30.1 months in the other group.. Cancer drug provided the green light to treat head and neck malignancy Taxotere Following promising benefits in a stage III trial, the drug Taxotere has been given the green light for use in people with head and neck tumor.It found five specific environmental factors, which the researchers call domains, that can predict adult depression, stress and anxiety and post-traumatic stress disorder. In the second study, released online by the journal Psychological Evaluation, researchers utilized the same five domains to build up a new screening tool for use in clinical configurations. The UCLA Life Adversities Screener, or LADS, is a short questionnaire that will help suppliers offer more accurate treatment for trauma and stress. The five domains determined in the first study are: Encounters of discrimination because of racial, ethnic, gender or sexual orientation A history of sexual abuse A brief history of violence in the family members or from an intimate partner A history of violence within an individuals' community A chronic concern with being killed or significantly injured The experts said the effects of these encounters are cumulative and their impact accrues over a person's lifetime.